
Vivus, Inc - Strategy, SWOT and Corporate Finance Report
Description
Vivus, Inc - Strategy, SWOT and Corporate Finance Report
Summary
Vivus, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Vivus, Inc. (Vivus or 'the company'), a subsidiary of Biopharma LLC, is a biopharmaceutical company focused on research, development, and commercialization of innovative and next-generation therapies which in turn addresses various medical needs of its patients. These products find application in cystic fibrosis, chronic pancreatitis, obesity, inflammatory bowel disease, and diabetes. Vivus's approved therapies include Qsymia and Pancreaze/Pancrease MT (pancrelipase). The company's pipeline product, Tacrolimus is being developed for the treatment of pulmonary arterial hypertension (PAH). Vivus markets its products under Qsymia and Pancreaze brand names. The company operations are spread across Australia, New Zealand, the US, and Rest of the World. The company is headquartered in Campbell, California, the US
Scope
Summary
Vivus, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Vivus, Inc. (Vivus or 'the company'), a subsidiary of Biopharma LLC, is a biopharmaceutical company focused on research, development, and commercialization of innovative and next-generation therapies which in turn addresses various medical needs of its patients. These products find application in cystic fibrosis, chronic pancreatitis, obesity, inflammatory bowel disease, and diabetes. Vivus's approved therapies include Qsymia and Pancreaze/Pancrease MT (pancrelipase). The company's pipeline product, Tacrolimus is being developed for the treatment of pulmonary arterial hypertension (PAH). Vivus markets its products under Qsymia and Pancreaze brand names. The company operations are spread across Australia, New Zealand, the US, and Rest of the World. The company is headquartered in Campbell, California, the US
Scope
- Detailed information on Vivus, Inc required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Vivus, Inc in the form of a SWOT analysis
- An in-depth view of the business model of Vivus, Inc including a breakdown and examination of key business segments
- Intelligence on Vivus, Inc's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Vivus, Inc, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
- Gain understanding of Vivus, Inc and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Vivus, Inc as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on Vivus, Inc's business structure, strategy and prospects.
Table of Contents
39 Pages
- Company Snapshot
- Vivus, Inc.: Company Overview
- Vivus, Inc.: Overview and Key Facts
- Vivus, Inc.: Overview
- Vivus, Inc.: Key Facts
- Vivus, Inc.: Key Employees
- Vivus, Inc.: Key Employee Biographies
- Vivus, Inc.: Major Products and Services
- Vivus, Inc.: Company History
- Vivus, Inc.: Locations and Subsidiaries
- Vivus, Inc.: Key Competitors
- Vivus, Inc.: Company Analysis
- Vivus, Inc.: Business Description
- Vivus, Inc.: SWOT Analysis
- Vivus, Inc.: SWOT Overview
- Vivus, Inc.: Strengths
- Vivus, Inc.: Weaknesses
- Vivus, Inc.: Opportunities
- Vivus, Inc.: Threats
- Vivus, Inc.: Corporate Financial Deals Activity
- Vivus, Inc.: Financial Deals Overview
- Vivus, Inc.: Top Deals 2018 - 2022YTD*
- Vivus, Inc.: Advisors
- Vivus, Inc.: Top Legal Advisors
- Vivus, Inc.: Mergers and Acquisitions
- Vivus, Inc.: Capital Raising
- Vivus, Inc.: Recent Developments
- Vivus, Inc.: News and Events Summary
- Vivus, Inc.: Contracts
- Vivus, Inc.: Corporate Governance
- Vivus, Inc.: Corporate Social Responsibility
- Vivus, Inc.: Financial Deals
- Vivus, Inc.: Financial Performance
- Appendix
- Contact Us
- Methodology
- About MarketLine
- List of Tables
- Table 1: Vivus, Inc.: Key Facts
- Table 2: Vivus, Inc.: Key Employees
- Table 3: Vivus, Inc.: Company History
- Table 4: Vivus, Inc.: Locations and Subsidiaries
- Table 5: Vivus, Inc.: Key Competitors
- Table 6: Vivus, Inc.: Deal Activity by Deal Type - Volume (2018 - YTD*2022)
- Table 7: Vivus, Inc.: M&A Average Deal Size - Value (US$m)
- Table 8: Vivus, Inc.: Top Deals 2018 - 2022YTD*
- Table 9: Vivus, Inc.: Legal Advisor Ranking by Value (US$m)
- Table 10: Vivus, Inc.: M&A Volume and Value Trend (2018 - YTD*2022)
- Table 11: Vivus, Inc.: Capital Raising Volume and Value Trend (2018 - YTD*2022)
- Table 12: Vivus, Inc.: Capital Raising by Deal Type (2018 - YTD*2022)
- Table 13: Vivus, Inc.: News and Events Summary
- Table 14: Vivus, Inc.: Contracts
- Table 15: Vivus, Inc.: Corporate Governance
- Table 16: Vivus, Inc.: Corporate Social Responsibility
- Table 17: Vivus, Inc.: Financial Deals
- Table 18: Vivus, Inc.: Financial Performance
- List of Figures
- Figure 1: Vivus, Inc.: Deal Activity by Deal Type - Volume (2018 - YTD*2022)
- Figure 2: Vivus, Inc.: M&A Average Deal Size - Value (US$m)
- Figure 3: Vivus, Inc.: M&A Volume and Value Trend (2018 - YTD*2022)
- Figure 4: Vivus, Inc.: Capital Raising Volume and Value Trend (2018 - YTD*2022)
- Figure 5: Vivus, Inc.: Capital Raising by Deal Type (2018 - YTD*2022)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.